



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Stormann et al.

**Serial No.:** 09/679,664

**Filed:** October 3, 2000

**For:** G-PROTEIN FUSION RECEPTORS  
AND CONSTRUCTS ENCODING SAME

**Confirmation No.:** 7662

**Examiner:** R. Landsman

**Group Art Unit:** 1647

**Attorney Docket No.:** 1959-7394US  
(N-019 US)

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

September 11, 2006  
Date

  
Signature

Timothy L. Palfreyman  
Name (Type/Print)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

09/15/2006 10:00:00 00000000 01578354

01 FC:1005

100.00 CF

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

Other Documents

Cotecchia et al., "Discrete Amino Acid Sequences of the  $\alpha_1$ -Adrenergic Receptor Determine the Selectivity of Coupling to Phosphatidylinositol Hydrolysis, J. Biol. Chem. 267:1633-1639 (1992).

Ferguson et al., "Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures", Ann. Rev. Biochem. 57:285-320 (1988).

Liggett et al., "Sites in the Third Intracellular Loop of the  $\alpha_{2A}$ -Adrenergic Receptor Confer Short Term Agonist-Promoted Desensitization", J. Biol. Chem. 267:4740-4746 (1992).

Okamoto et al., "Identification of a  $G_s$  Activator Region of the  $\beta_2$ -Adrenergic Receptor that is Autoregulated via Protein Kinase A-Dependent Phosphorylation", Cell 67:723-730 (1991).

Wang et al., "Identification of a Domain in the Angiotensin II Type 1 Receptor Determining  $G_q$  Coupling by the Use of Receptor Chimeras", J. Biol. Chem. 270:16677-16682 (1995).

Wong et al., "Chimeric Muscarinic Cholinergic: $\beta$ -Adrenergic Receptors That Activate  $G_s$  in Response to Muscarinic Agonists", J. Biol. Chem. 265:6219-6224 (1990).

**Serial No. 09/679,664**

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



Edgar R. Cataxinos  
Registration No. 39,931  
Attorney for Applicants  
TRASKBRITT  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: September 11, 2006


ERC/dn:tlp

Enclosures: Form PTO/SB/08 (1 page)

Copies of any Cited Non-U.S. Patent Documents (6 documents)

Check No. 10149 in the amount of \$180.00

Document in ProLaw



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	09/679,664
Filing Date	October 3, 2000
First Named Inventor	Stormann et al.
Group Art Unit	1647
Examiner Name	R. Landsman
Attorney Docket Number	1959-73941US (N-019 US)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Cotecchia et al., "Discrete Amino Acid Sequences of the $\alpha 1$ -Adrenergic Receptor Determine the Selectivity of Coupling to Phosphatidylinositol Hydrolysis", <u>J. Biol. Chem.</u> 267:1633-1639 (1992).	
		Ferguson et al., "Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures", <u>Ann. Rev. Biochem.</u> 57:285-320 (1988).	
		Liggett et al., "Sites in the Third Intracellular Loop of the $\alpha 2A$ -Adrenergic Receptor Confer Short Term Agonist-Promoted Desensitization", <u>J. Biol. Chem.</u> 267:4740-4746 (1992).	
		Okamoto et al., "Identification of a G <sub>i</sub> Activator Region of the $\beta 2$ -Adrenergic Receptor that is Autoregulated via Protein Kinase A-Dependent Phosphorylation", <u>Cell</u> 67:723-730 (1991).	
		Wang et al., "Identification of a Domain in the Angiotensin II Type I Receptor Determining G <sub>q</sub> Coupling by the Use of Receptor Chimeras", <u>J. Biol. Chem.</u> 270:16677-16682 (1995).	
		Wong et al., "Chimeric Muscarinic Cholinergic: $\beta$ -Adrenergic Receptors That Activate G <sub>i</sub> in Response to Muscarinic Agonists", <u>J. Biol. Chem.</u> 265:6219-6224 (1990).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.